These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19547873)

  • 1. Effectiveness and safety of isoniazid chemoprophylaxis for HIV-1 infected patients from Rio de Janeiro.
    Souza CT; Hökerberg YH; Pacheco SJ; Rolla VC; Passos SR
    Mem Inst Oswaldo Cruz; 2009 May; 104(3):462-7. PubMed ID: 19547873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease.
    Graham NM; Galai N; Nelson KE; Astemborski J; Bonds M; Rizzo RT; Sheeley L; Vlahov D
    Arch Intern Med; 1996 Apr; 156(8):889-94. PubMed ID: 8774208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis.
    Gourevitch MN; Hartel D; Selwyn PA; Schoenbaum EE; Klein RS
    AIDS; 1999 Oct; 13(15):2069-74. PubMed ID: 10546859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician adherence to guidelines for tuberculosis and HIV care in Rio de Janeiro, Brazil.
    Saraceni V; Pacheco AG; Golub JE; Vellozo V; King BS; Cavalcante SC; Eldred L; Chaisson RE; Durovni B
    Braz J Infect Dis; 2011; 15(3):249-52. PubMed ID: 21670926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
    ; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
    N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients.
    Casado JL; Moreno S; Fortún J; Antela A; Quereda C; Navas E; Moreno A; Dronda F
    Clin Infect Dis; 2002 Feb; 34(3):386-9. PubMed ID: 11753825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial.
    Hawken MP; Meme HK; Elliott LC; Chakaya JM; Morris JS; Githui WA; Juma ES; Odhiambo JA; Thiong'o LN; Kimari JN; Ngugi EN; Bwayo JJ; Gilks CF; Plummer FA; Porter JD; Nunn PP; McAdam KP
    AIDS; 1997 Jun; 11(7):875-82. PubMed ID: 9189212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study of the risk of tuberculosis among HIV-infected patients.
    Guelar A; Gatell JM; Verdejo J; Podzamczer D; Lozano L; Aznar E; Miró JM; Mallolas J; Zamora L; González J
    AIDS; 1993 Oct; 7(10):1345-9. PubMed ID: 8267907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus. The GECMEI Group].
    Martínez Alfaro EM; Cuadra F; Solera J; Maciá MA; Geijo P; Sánchez Martínez PA; Rodríguez Zapata M; Largo J; Sepúlveda MA; Rosa C; Sánchez L; Espinosa A; Mateos F; Blanch JJ
    Med Clin (Barc); 2000 Jul; 115(5):161-5. PubMed ID: 10996870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of clinical tuberculosis in HIV-infected males with isoniazid prophylaxis.
    Alaei K; Alaei A; Mansouri D
    East Mediterr Health J; 2002 Nov; 8(6):754-7. PubMed ID: 15568452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis.
    Jansà JM; Serrano J; Caylà JA; Vidal R; Ocaña I; Español T
    Int J Tuberc Lung Dis; 1998 Feb; 2(2):140-6. PubMed ID: 9580481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival.
    Moreno S; Miralles P; Diaz MD; Baraia J; Padilla B; Berenguer J; Alberdi JC
    Arch Intern Med; 1997 Aug 11-25; 157(15):1729-34. PubMed ID: 9250234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS.
    Gordin FM; Matts JP; Miller C; Brown LS; Hafner R; John SL; Klein M; Vaughn A; Besch CL; Perez G; Szabo S; El-Sadr W
    N Engl J Med; 1997 Jul; 337(5):315-20. PubMed ID: 9233868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial.
    Fitzgerald DW; Desvarieux M; Severe P; Joseph P; Johnson WD; Pape JW
    Lancet; 2000 Oct; 356(9240):1470-4. PubMed ID: 11081529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children.
    Madhi SA; Nachman S; Violari A; Kim S; Cotton MF; Bobat R; Jean-Philippe P; McSherry G; Mitchell C;
    N Engl J Med; 2011 Jul; 365(1):21-31. PubMed ID: 21732834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.
    Halsey NA; Coberly JS; Desormeaux J; Losikoff P; Atkinson J; Moulton LH; Contave M; Johnson M; Davis H; Geiter L; Johnson E; Huebner R; Boulos R; Chaisson RE
    Lancet; 1998 Mar; 351(9105):786-92. PubMed ID: 9519950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang Rai, Thailand.
    Ngamvithayapong J; Uthaivoravit W; Yanai H; Akarasewi P; Sawanpanyalert P
    AIDS; 1997 Jan; 11(1):107-12. PubMed ID: 9110083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness of prophylaxis against tuberculosis in patients infected with HIV].
    Arbeláez MP; Arbeláez A; Gómez RD; Rojas C; Vélez L; Arias SL; Nagles J; Peláez LM; Betancourt G; Velásquez G
    Biomedica; 2007 Dec; 27(4):515-25. PubMed ID: 18320119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre.
    Aisu T; Raviglione MC; van Praag E; Eriki P; Narain JP; Barugahare L; Tembo G; McFarland D; Engwau FA
    AIDS; 1995 Mar; 9(3):267-73. PubMed ID: 7755915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculin skin test and chemoprophylaxis of tuberculosis.
    Ortona L; Fantoni M
    Rays; 1998; 23(1):218-24. PubMed ID: 9673147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.